RxDoctor Payments DataLook up a doctor →

Kevin Williams, PA

Physician Assistant · Tampa, FLNPI 1841687829

Payments from drug & device makers

$647,303in general payments, 2019–2025

Across 1,016 payments — averaging $637.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$452K
  • Teva Pharmaceuticals USA, Inc.$87K
  • AbbVie$37K
  • Axsome Therapeutics, Inc.$32K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
  • Alkermes, Inc.$6K
  • plus $12K from 14 others

What the payments were for

  • Consulting fees$85,24313%
  • Speaking & faculty fees$432,57567%
  • Travel & lodging$102,98616%
  • Food & beverage$26,4144%
  • Education$860%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$647,303 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$107,569
Medicare patients
320
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$363,243
Invega SustennaPaliperidone Palmitate28$96,767
VraylarCariprazine Hcl58$87,745
NuedextaDextromethorphan Hbr/Quinidine14$22,154
AuvelityDextromethorphan Hbr/Bupropion15$11,877
Desvenlafaxine Succinate ErDesvenlafaxine Succinate38$2,116
Bupropion XlBupropion Hcl57$1,073
Alprazolam144$873
Aripiprazole19$802
Clonazepam75$749
Lorazepam126$580
Albuterol Sulfate HfaAlbuterol Sulfate17$575
Oxcarbazepine13$544
Olanzapine45$530
Divalproex Sodium42$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$452,484$363,24345 claims
Johnson & JohnsonInvega Sustenna$112$96,76728 claims
AbbVieVraylar$36,548$87,74558 claims
Axsome Therapeutics, Inc.Auvelity$32,288$11,87715 claims
Almatica Pharma LLCSertraline Hcl$57$4918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →